Table 1.

Clinicopathologic Features of Patients With HCC

Patient demographics and tumor characteristics	Patients (N = 19)
Age, median (IQR)	53.5 (44.0–62.0)
Male/female, n	16/3
HBV/NASH/HCV/alcohol	10/5/3/1
Child Pugh Score, A/B/C	19/0/0
MELD, median (IQR)	7 (7–9)
AFP, median (IQR), ng/mL	25.0 (6.0–639.0)
Tumor total diameter, >5/<5 (cm), n	14/5
Vascular invasion, n	9
BCLC stage, 0 or A/B or C, n	10/9
Tumor grade among engrafted human HCC: well differentiated, moderately differentiated, poorly differentiated, n	0/1/7
Tumor grade among nonengrafted human HCC: well differentiated, moderately differentiated, poorly differentiated, n	1/8/2

AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C; IQR, interquartile range; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis.